Hipoacusia como primera manifestación de granulomatosis con poliangeítis

[Hypoacusis as the first manifestation of granulomatosis with polyangiitis ]

Abdullah Salehji1, Ricardo Moreno2, Diego Arcia3, Rolando Milrod3

1. Departamento de Medicina Interna, Complejo Hospitalario Doctor Arnulfo Arias Madrid, Panamá, Rep. de Panamá; 2. Nefrología, Complejo Hospitalario Doctor Arnulfo Arias Madrid, Panamá, Rep. de Panamá; 3. Departamento de Patología, Complejo Hospitalario Doctor Arnulfo Arias Madrid, Panamá, Rep. de Panamá.

Publicado: 2023-01-27

Descargas

Archivos adicionales

Resumen

Introducción: Las vasculitis asociadas a anticuerpos anti citoplasma de neutrófilos (ANCA) son entidades clínicas poco frecuentes con manifestaciones amplias que se asocian a retos diagnósticos. El tratamiento oportuno se asocia a mejoría pronóstica significativa.

Caso clínico: Femenina de 45 años que acude con síntomas constitucionales de 2 meses de evolución, asociado en las últimas 2 semanas a hipoacusia progresiva. Se evidencia lesión renal aguda asociada a datos de sedimento urinario activo. El perfil inmune solicitado resultó positivo para ANCA PR-3, y la biopsia renal confirma el diagnóstico de Granulomatosis con Poliangeitis. Se inicia tratamiento inmunosupresor con ciclofosfamida, con poca mejoría de la función renal y requerimiento de hemodiálisis crónica.  La amplia variedad de manifestaciones clínicas asociadas a las vasculitis ANCA conducen a la incapacidad de diagnosticarlas tempranamente y la hipoacusia, aunque descrita, es una manifestación inicial poco frecuente. Conclusión: Las VAA son entidades clínicas poco frecuentes y cuando se presentan con manifestaciones atípicas, suelen ser un reto diagnóstico. Resulta imperativo considerarla en casos de síntomas constitucionales, asociados a manifestaciones renales, otorrinolaringológicas y pulmonares.


Abstract

Introduction: Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides are rare clinical entities with broad manifestations that are associated with diagnostic challenges. Prompt treatment is associated with significant prognostic improvement. Case report: 45-year-old female presenting with constitutional symptoms of 2 months of evolution, associated in the last 2 weeks with progressive hypoacusis. Acute renal lesion associated with active urinary sediment data was evidenced. The requested immune profile was positive for ANCA PR-3, and the renal biopsy confirmed the diagnosis of Granulomatosis with Polyangiitis. Immunosuppressive treatment with cyclophosphamide was started, with little improvement in renal function and requiring chronic hemodialysis.

The wide variety of clinical manifestations associated with ANCA vasculitis lead to the inability to diagnose them early and hypoacusis, although described, is a rare initial manifestation. Conclusion: AAV are rare clinical entities and when they present with atypical manifestations, they are often a diagnostic challenge. It is imperative to consider it in cases of constitutional symptoms, associated with renal, otorhinolaryngologic and pulmonary manifestations.

Citas

[1] Xavier Paschal. Granulomatosis with Polyangiitis. Joint Bone Spine. 2020 Dec;87(6):572-578.

[2] Kitching AR, Anders HJ, Basu N, Brouwer E, Gordon J, Jayne DR, Kullman J, Lyons PA, Merkel PA, Savage COS, Specks U, Kain R. ANCA-associated vasculitis. Nat Rev Dis Primers. 2020 Aug 27;6(1):71.

[3] Kariv, R., Sidi, Y. & Gur, H. Systemic vasculitis presenting as a tumorlike lesion. Four case reports and an analysis of 79 reported cases. Medicine 79, 2000, 349–359.

[4] Greco A, Marinelli C, Fusconi M, Macri GF, Gallo A, De Virgilio A, Zambetti G, de Vincentiis M. Clinic manifestations in granulomatosis with polyangiitis. Int J Immunopathol Pharmacol. 2016 Jun;29(2):151-9. doi: 10.1177/0394632015617063.

[5] Dekker PJ (2009) Wegener granulomatosis: Otological aspects. Journal of Otolaryngology 22: 364–367.

[6] Gómez-Puerta JA, Hernández-Rodríguez J, López-Soto A, Bosch X. Antineutrophil cytoplasmic antibody-associated vasculitis’s and respiratory disease. Chest. 2018 Oct;136(4):1101-1111. doi: 10.1378/chest.08-3043. PMID: 19809051.

[7] Seo P, Stone JH. The antineutrophil cytoplasmic antibody-associated vasculitis. Am J Med 2004; 117:39

[8] Geetha D, Jefferson JA. ANCA-Associated Vasculitis: Core Curriculum 2020. Am J Kidney Dis. 2020 Jan;75(1):124-137. doi: 10.1053/j.ajkd.2019.04.031. Epub 2019 Jul 26. PMID: 31358311.

[9] Lyons PA, Rayner TF, Trivedi S, et al. Genetically distinct subsets within ANCA-associated vasculitis. N Engl J Med. 2012;367(3):214–223. doi:10.1056/NEJMoa1108735.

[10] Merkel PA, Xie G, Monarch PA, et al.; for Vasculitis Clinical Research Consortium. Identification of functional and expression polymorphisms associated with risk for antineutrophil cytoplasmic autoantibody-associated vasculitis. Arthritis Rheumatol. 2017;69(5):1054–1066. doi:10.1002/art.40034.

[11] Popa ER, Stegeman CA, Abdulahad WH, et al. Staphylococcal toxic-shock-syndrome-toxin-1 as a risk factor for disease relapse in Wegener’s granulomatosis. Rheumatology. 2007;46(6):1029–1033. doi:10.1093/rheumatology/kem022.

[12] Giorgiutti S, Dieudonne Y, Hinschberger O, et al. Prevalence of antineutrophil cytoplasmic antibody-associated vasculitis and spatial association with quarries in a region of northeastern France: a capture-recapture and geospatial analysis. Arthritis Rheumatol. 2021; 73:2078–2085. doi:10.1002/art.41767.

[13] Jin Q, Kant S, Alhariri J, Geetha D. Levamisole adulterated cocaine associated ANCA vasculitis: review of literature and update on pathogenesis. J Community Hosp Intern Med Perspect. 2018;8(6):339–344. doi:10.1080/20009666.2018.1536242.

[14] Austin K, Janagan S, Wells M, Crawshaw H, McAdoo S, Robson JC. ANCA Associated Vasculitis Subtypes: Recent Insights and Future Perspectives. J Inflamm Res. 2022 Apr 21; 15:2567-2582. doi: 10.2147/JIR.S284768.

[15] Hunder GG, Arend WP, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of vasculitis. Introduction. Arthritis Rheum. 1990;33(8):1065–1067. doi:10.1002/art.1780330802.

[16] Suppiah R, Robson JC, Grayson PC, et al.2022 American College of Rheumatology/ European Alliance of Associations for Rheumatology classification criteria for microscopic polyangitis. Arthritis & Rheumatology. 2022 Mar; 74(3):400-6.

[17] Grayson PC, Ponte C, Suppiah R, et al. 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for eosinophilic granulomatosis with polyangiitis. Arthritis & Rheumatology. 2022 Mar; 74(3):386-92.

[18] Robson JC, Grayson PC, Ponte C, et al. 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for granulomatosis with polyangiitis. Arthritis & Rheumatology. 2022 Mar;74(3):393-9. 18

[19] Yates M, Watts RA, Bajema IM, et al. EULAR/ ERA-EDTA recommendations for the management of ANCA associated vasculitis. Ann Rheum Dis. 2016;75(9):1583–1594. doi:10.1136/annrheumdis-2016-209133.

[20] McAdoo SP, Medjeral-Thomas N, Gopaluni S, et al. Long-term follow-up of a combined rituximab and cyclophosphamide regimen in renal anti-neutrophil cytoplasm antibody-associated vasculitis. Nephrol Dial Transplant. 2019;34(1):63–73. doi:10.1093/ndt/gfx378.

[21] Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int. 2021 Oct;100(4S):S1-S276. doi: 10.1016/j.kint.2021.05.021.

[22] Jones RB, Furuta S, Tervaert JWC, et al; for European Vasculitis Society (EUVAS). Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial. Ann Rheum Dis. 2015;74(6):1178–1182. doi:10.1136/annrheumdis-2014-206404.

[23] Jayne DR, Merkel PA, Schall TJ, Bekker P; ADVOCATE Study Group. Avacopan for the treatment of ANCA-associated vasculitis. N Engl J Med. 2021;384(7):599–609. doi:10.1056/NEJMoa2023386. 23

[24] Jones RB, Tervaert JW, Hauser T, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med. 2010; 363:211–220. 24

[25] Unizony S, Villarreal M, Miloslavsky EM, et al. Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type. Ann Rheum Dis. 2016; 75:1166–1169.

×